Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 11 Apr 2025
A meta-analysis of 27 trials found no increased risk of suicide or self-harm with GLP-1 RAs, supporting their safety for diabetes and obesity management.
Read Full NewsClinical Crosstalk: Integrating ICIs and Strengthening Collaborative Care in NMSC
More late-stage diagnoses add to higher cancer mortality burden for men
IMACS guidelines are clinically useful for identifying high-risk populations, researchers say
Kids are microwaving the squishy toy, making the gel inside hot enough to boil and explode
Dermatologists weigh in on the injectable trend
Health news and commentary gathered by MedPage Today staff
Replimune's RP1 faces tough test at upcoming FDA advisory panel meeting
1.
Teenagers Frequently Use Delta-8 THC; New Drug-Coated Balloon Treats Blocked Stents.
2.
Even a few mutated cells can significantly impact how blood cancers develop, study finds
3.
GLP-1 RAs May Lower Hysterectomy Risk in Endometrial Cancer
4.
Advanced Solid Tumors May Benefit from Investigative Immunotherapy Combo.
5.
In Acute Leukemia With Heavily Pretreated Patients, Menin Inhibitor Yields 63 Percent ORR.
1.
Understanding Epoetin and Its Role in Treating Chronic Kidney Disease
2.
First-Line Immuno-Hematology Examinations: Essential Diagnostic Tools for Patient Care
3.
Hematopoietic Recovery Potential and Long-Term Survival: Mechanisms, Clinical Impact, and Emerging Directions
4.
Recombinant ADAMTS13: Advancing Prophylaxis in Congenital TTP Management
5.
Fc Receptor Mediated Pharmacology of Therapeutic Antibodies
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
2.
Oropharyngeal Cancer in Relation to HPV Status
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
4.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
5.
Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge